{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:18:17Z","timestamp":1770646697583,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jns.2017.11.019","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T04:17:10Z","timestamp":1511151430000},"page":"199-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Clinical management of tardive dyskinesia: Five steps to success"],"prefix":"10.1016","volume":"383","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jns.2017.11.019_bb0005","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","article-title":"On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not","volume":"13","author":"Citrome","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2017.11.019_bb0010","author":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.jns.2017.11.019_bb0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jns.2017.11.019_bb0020","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2017.11.019_bb0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2017.11.019_bb0030","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"11","key":"10.1016\/j.jns.2017.11.019_bb0035","first-page":"1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz","year":"1988","journal-title":"Hosp. Commun. Psychiatry"},{"key":"10.1016\/j.jns.2017.11.019_bb0040","author":"Neurocrine Biosciences"},{"key":"10.1016\/j.jns.2017.11.019_bb0045","author":"Teva Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.jns.2017.11.019_bb0050","doi-asserted-by":"crossref","first-page":"e12964","DOI":"10.1111\/ijcp.12964","article-title":"Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"71","author":"Citrome","year":"2017","journal-title":"Int. J. Clin. Pract."},{"issue":"11","key":"10.1016\/j.jns.2017.11.019_bb0055","doi-asserted-by":"crossref","first-page":"e13030","DOI":"10.1111\/ijcp.13030","article-title":"Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"71","author":"Citrome","year":"2017","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.jns.2017.11.019_bb0060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2017.11.019_bb0065","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","article-title":"Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study","volume":"50","author":"Morgenstern","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2017.11.019_bb0070","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"2 Suppl","key":"10.1016\/j.jns.2017.11.019_bb0075","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2017.11.019_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00002018-199920030-00006","article-title":"Managing antipsychotic-induced parkinsonism","volume":"20","author":"Mamo","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.jns.2017.11.019_bb0085","author":"Merck"},{"issue":"Suppl","key":"10.1016\/j.jns.2017.11.019_bb0090","first-page":"1","article-title":"Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders","volume":"13","author":"Citrome","year":"2007","journal-title":"Am. J. Manag. Care"},{"issue":"8","key":"10.1016\/j.jns.2017.11.019_bb0095","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","article-title":"Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment","volume":"78","author":"Correll","year":"2017","journal-title":"J. Clin. Psychiatry."},{"issue":"9","key":"10.1016\/j.jns.2017.11.019_bb0100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2017.11.019_bb0105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.jns.2017.11.019_bb0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1176\/appi.ajp.160.6.1117","article-title":"Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men","volume":"160","author":"Richardson","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2017.11.019_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2017.11.019_bb0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/pcn.12270","article-title":"Tardive dyskinesia (syndrome): current concept and modern approaches to its management","volume":"69","author":"Lerner","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2017.11.019_bb0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2017.11.019_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0042-102884","article-title":"Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials","volume":"49","author":"Zheng","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.jns.2017.11.019_bb0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.jns.2017.11.019_bb0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2017.11.019_bb0145","author":"Adamas Pharma"},{"key":"10.1016\/j.jns.2017.11.019_bb0150","author":"Lundbeck"},{"issue":"4","key":"10.1016\/j.jns.2017.11.019_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","article-title":"Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders","volume":"8","author":"Guay","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"issue":"7","key":"10.1016\/j.jns.2017.11.019_bb0160","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","article-title":"Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature","volume":"34","author":"Chen","year":"2012","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.jns.2017.11.019_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia, I: clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2017.11.019_bb0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2017.11.019_bb0175","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2017.11.019_bb0180","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2017.11.019_bb0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"21","key":"10.1016\/j.jns.2017.11.019_bb0190","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2017.11.019_bb0195","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2017.11.019_bb0200","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.jns.2017.11.019_bb0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int. J. Clin. Pract."},{"issue":"10","key":"10.1016\/j.jns.2017.11.019_bb0210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/da.21983","article-title":"Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians","volume":"29","author":"Yeung","year":"2012","journal-title":"Depress Anxiety"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17344519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17344519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:42:22Z","timestamp":1750999342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17344519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":42,"alternative-id":["S0022510X17344519"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.11.019","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical management of tardive dyskinesia: Five steps to success","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}